Cancer-Killing virus trial launches for Hard-to-Treat tumors
NCT ID NCT05914376
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a modified virus called hV01 in 24 adults with advanced solid tumors that have not responded to standard treatments. The virus is injected directly into tumors and is designed to kill cancer cells while also boosting the immune system. The main goals are to check safety, find the right dose, and see how the virus behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a modified vaccinia virus (hV01) that carries a human immune-boosting protein (IL-21)
- What this could lead to
- If it works, this could point toward a new way to shrink advanced solid tumors by using a virus to attack cancer cells and boost the immune system.
- What could go wrong
- This is a very early (Phase 1) trial with only 24 people, so it is mainly checking safety. The virus may not work well in all patients, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Zhejiang People's Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.